<DOC>
	<DOCNO>NCT02929316</DOCNO>
	<brief_summary>Celiac disease ( CD ) characterize autoimmune disorder whereby gluten ( protein find wheat , barley , rye , malt ) induce immunological response genetically susceptible individual . The prevalence CD estimate affect 0.5-1 % population worldwide . Long term sequelae numerous include risk lymphoma , malabsorption lead weight loss , anemia , multiple vitamin deficiency , osteoporosis/osteopenia , secondary autoimmunity , etc . ( 1 )</brief_summary>
	<brief_title>Vedolizumab Induction May Prevent Celiac Enteritis</brief_title>
	<detailed_description>Adult subject CD recruit clinic . All patient enrol establish CD diagnose &gt; 6 month . All patient history abnormal MARSH score initial duodenal biopsy diagnosis MARSH 0 repeat biopsy follow gluten free diet ( GFD ) . All patient also positive celiac serology ( anti-TTG , anti-gliadin , etc . ) diagnosis , well , positive HLA DQ2/DQ8 genetic profile . At enrollment , patient negative celiac serology , indicative serologic remission gluten free diet . Female subject childbearing potential ( include history tubal ligation/surgical sterilization , hysterectomy and/or oophorectomy ) sexually active non-sterilized male partner agree routinely use adequate contraception signing informed consent , study process additional 18 week last dose vedolizumab . A male subject non-sterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 18 week last dose .</detailed_description>
	<mesh_term>Celiac Disease</mesh_term>
	<mesh_term>Enteritis</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>Patients must meet follow criterion study entry : Adult patient Celiac Disease ( CD ) Without additional comorbidities Normal renal hepatic function Diagnosis CD establish least 6 month prior trial diagnostic serology , genetic profile , endoscopic appearance histopathology report In histologic serologic remission ( define MARSH 0 negative antitissue transglutaminase , etc . ) follow gluten free diet Na√Øve treatment vedolizumab Able willing provide write informed consent Eligibility criterion laboratory profile healthy patient normal laboratory reference value WBC 4.512.0 k/UL Platelet count 140415 k/UL Hemoglobin 11.017.4 % g/dL Renal Function Creatinine 0.51.3 mg/dL BUN 520 mg/dL Hepatic Function Albumin 3.35.0 g/dL INR 0.91.1 AST 037 U/L ALT 040 U/L Total Bilirubin 0.11.3 mg/dL Alk Phos 35150 U/L Patients meet follow criterion exclude study entry : Abnormal MARSH score enrollment histopathology Elevated celiac serology ( antitissue transglutaminase , etc . ) Current use biologics immunomodulators Adalimumab , infliximab , Ustekinumab , Golimumab , Tocilizumab , Certolizumab , Etanercept , Rituximab , Anakinra , Abatacept , Tofacitinib , Methotrexate , Azathioprine , 6MP . Current use immunosuppressive therapy include intermittent systemic corticosteroid within two month vedolizumab induction History intestinal lymphoma ( MALToma , etc . ) History cancer include hematologic malignancy , solid tumor , carcinoma situ , etc . Pregnant lactate Fertile female require least one form birth control Lack peripheral venous access Inability comply study protocol , opinion investigator Neurological condition may interfere monitor PML History demyelinate disease history major neurological disease History alcohol , drug chemical abuse &lt; 6 month prior screen History active tuberculosis ( TB ) positive screen test latent mycobacterium tuberculosis infection Positive PPD= &gt; 10 mm &gt; 5mm patient 15 mg prednisone History BCG vaccination screen use Quantiferon TB Gold test An Indeterminate Quantiferon test require chest Xray rule active TB consultation infectious disease specialist confirm risk latent TB low patient safely enrolled trial History recurrent opportunistic infection and/or severe disseminate viral infection Active autoimmune disease Active inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>